Dr. Arvinder Soin discusses the use of tocilizumab plus standard care versus standard care alone in the treatment of moderate to severe COVID-19-associated cytokine release syndrome.
Read the full article:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00081-3/fulltext
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv